Compared to that in the model group, the protein expression of Wnt3a (p < 0.05) and β-catenin (p < 0.01) was significantly inhibited in the BMSC treatment group, while the expression of p-GSK3β in the BMSC treatment group was significantly increased (p < 0.01), which suggested that BMSCs could effectively activate GSK3β and inhibit the Wnt/β-catenin signalling pathway in rat liver fibrosis. The gene discussed is WNT3A; the disease is Hepatic fibrosis.